Abstract
Background:
Current methods for the detection of single nucleotide polymorphisms (SNPs) associated with aberrant drug-metabolizing enzyme function are hindered by long turnaround times and specialized techniques and instrumentation. In this study, we describe the development and validation of a high-resolution melting (HRM) curve assay for the rapid screening of variant genotypes for targeted genetic polymorphisms in the cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP3A5.
Methods:
Sequence-specific primers were custom-designed to flank nine SNPs within the genetic regions of aforementioned drug metabolizing enzymes. PCR amplification was performed followed by amplicon denaturation by precise temperature ramping in order to distinguish genotypes by melting temperature (Tm). A standardized software algorithm was used to assign amplicons as ‘reference’ or ‘variant’ as compared to duplicate reference sequence DNA controls for each SNP.
Results:
Intra-assay (n=5) precision of Tms for all SNPs was ≤0.19%, while inter-assay (n=20) precision ranged from 0.04% to 0.21%. When compared to a reference method of Sanger sequencing, the HRM assay produced no false negative results, and overcall frequency ranged from 0% to 26%, depending on the SNP. Furthermore, HRM genotyping displayed accuracy over input DNA concentrations ranging from 10 to 200 ng/μL.
Conclusions:
The presented assay provides a rapid method for the screening for genetic variants in targeted CYP450 regions with a result of ‘reference’ or ‘variant’ available within 2 h from receipt of extracted DNA. The method can serve as a screening approach to rapidly identify individuals with variant sequences who should be further investigated by reflexed confirmatory testing for aberrant cytochrome P450 enzymatic activity. Rapid knowledge of variant status may aid in the avoidance of adverse clinical events by allowing for dosing of normal metabolizer patients immediately while identifying the need to wait for confirmatory testing in those patients who are likely to possess pharmacogenetically-relevant variants.
Acknowledgments
The authors gratefully acknowledge Dr. and Mrs. Cornelius Borman for their generous gift that supported the purchase of the instrumentation used in this study. This publication resulted in part from research supported by the Johns Hopkins University Center for AIDS Research, an NIH funded program (P30AI094189), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. We also acknowledge the Johns Hopkins Genetic Resources Core Facility for their services. In particular, we acknowledge Roxann Ashworth of the Johns Hopkins Genetic Resources Core Facility and Katie Beierl of the Johns Hopkins Molecular Diagnostics Laboratory for their guidance.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Petrides AK, Clarke W, Marzinke MA. Application and Utility of Pharmacogenetics in the Clinical Laboratory. J Analyt Molecul Tech 2014;1:15.Search in Google Scholar
2. Gundry CN, Vandersteen JG, Reed GH, Pryor RJ, Chen J, Wittwer CT. Amplicon melting analysis with labeled primers: a closed-tube method for differentiating homozygotes and heterozygotes. Clin Chem 2003;49:396–406.10.1373/49.3.396Search in Google Scholar PubMed
3. Reed GH, Kent JO, Wittwer CT. High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 2007;8:597–608.10.2217/14622416.8.6.597Search in Google Scholar PubMed
4. Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006;6:295.10.1186/1471-2407-6-295Search in Google Scholar PubMed PubMed Central
5. Norambuena PA, Copeland JA, Křenková P, Štambergová A, Macek Jr A. Diagnostic method validation: high resolution melting (HRM) of small amplicons genotyping for the most common variants in the MTHFR gene. Clin Biochem 2009;42:1308–16.10.1016/j.clinbiochem.2009.04.015Search in Google Scholar PubMed
6. Singh RR, Bains A, Patel KP, Rahimi H, Barkoh BA, Paladugu A, et al. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn 2012;14:336–45.10.1016/j.jmoldx.2012.02.009Search in Google Scholar PubMed PubMed Central
7. Song C, Castellanos-Rizaldos E, Bejar R, Ebert BL, Makrigiorgos GM. DMSO increases mutation scanning detection sensitivity of high-resolution melting in clinical samples. Clin Chem 2015;61:1354–62.10.1373/clinchem.2015.245357Search in Google Scholar PubMed PubMed Central
8. van der Stoep N, van Paridon CD, Janssens T, Krenkova P, Stambergova A, Maeck M, et al. Diagnostic guidelines for high-resolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well LightScanner. Hum Mutat 2009;30:899–909.10.1002/humu.21004Search in Google Scholar PubMed
9. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008;21:70–83.10.1021/tx700079zSearch in Google Scholar PubMed
10. Zanger UM, Turpeinen M, Klein K, Schwab, M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008;392:1093–1108.10.1007/s00216-008-2291-6Search in Google Scholar PubMed
11. Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011;89:464–7.10.1038/clpt.2010.279Search in Google Scholar PubMed PubMed Central
12. FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. Available at: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed: June 2016.Search in Google Scholar
13. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 2014;95:376–82.10.1038/clpt.2013.254Search in Google Scholar
14. Moaddeb J, Haga SB. Pharmacogenetic testing: current evidence of clinical utility. Ther Adv Drug Saf 2013;4:155–69.10.1177/2042098613485595Search in Google Scholar
15. Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford, MA, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharm Theraput 2012;92:235–42.10.1038/clpt.2012.66Search in Google Scholar
16. Relling MV, Evans, WE. Pharmacogenomics in the clinic. Nature 2015;526:343–50.10.1038/nature15817Search in Google Scholar
17. Preissner SC, Hoffmann MF, Preissner R, Dunkel M, Gewiess A, Preissner S. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One 2013;8:e82562.10.1371/journal.pone.0082562Search in Google Scholar
18. Saab Y, Langaee T. Genetic Polymorphisms of CYP2C9: comparison of prevalence in the Lebanese population with other populations. Pharmacol Pharm 2011;2:88–93.10.4236/pp.2011.22011Search in Google Scholar
19. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002;54:1257–70.10.1016/S0169-409X(02)00076-5Search in Google Scholar
20. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011;90:625–9.10.1038/clpt.2011.185Search in Google Scholar PubMed PubMed Central
21. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 2015;98:19–24.10.1002/cpt.113Search in Google Scholar PubMed PubMed Central
22. Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics 2012;22:555–8.10.1097/FPC.0b013e328351d47fSearch in Google Scholar PubMed PubMed Central
23. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002;48:1668–71.10.1093/clinchem/48.10.1668Search in Google Scholar
24. Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y, et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 2002;58:417–21.10.1007/s00228-002-0499-5Search in Google Scholar PubMed
25. Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc 2008;83:66–76.10.4065/83.1.66Search in Google Scholar PubMed
26. Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 2010;20:277–81.10.1097/FPC.0b013e3283349e84Search in Google Scholar PubMed PubMed Central
27. Scott SA, Sangkuhl K, Shuldiner AR, Hulot J, Thorn CF, Altman RB, et al. PharmGKB summary: very important pharmacogene information cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics 2012;22:159–65.10.1097/FPC.0b013e32834d4962Search in Google Scholar PubMed PubMed Central
28. Lam NY, Rainer TH, Chiu RW, Lo YM. EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Clin Chem 2004;50:256–7.10.1373/clinchem.2003.026013Search in Google Scholar PubMed
29. Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther 2008;85:781–87.10.1038/sj.clpt.6100507Search in Google Scholar PubMed
30. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte – an update of guidelines. Clin Pharmacol Ther 2011;89:662–73.10.1038/clpt.2011.34Search in Google Scholar PubMed
31. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, et al. Preemptive clinical pharmacogenetics implementation: current programs in five United states medical centers. Annu Rev Pharmacol Toxicol 2015;55:89–106.10.1146/annurev-pharmtox-010814-124835Search in Google Scholar PubMed PubMed Central
Supplemental Material:
The online version of this article (DOI: 10.1515/cclm-2016-0603) offers supplementary material, available to authorized users.
©2017 Walter de Gruyter GmbH, Berlin/Boston